Previous 10 | Next 10 |
NEW YORK , Sept. 10, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating: Principia Biopharma Inc. (NASDAQ: PRNB) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties r...
NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may ultimately s...
NEW YORK, NY / ACCESSWIRE / September 3, 2020 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relati...
NEW YORK , Sept. 1, 2020 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP ...
NEW YORK, NY / ACCESSWIRE / August 28, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Pfenex Inc. (NYSE American: PFNX ) relating to its sa...
One of the most common reasons people don't start a stock portfolio is that they think they can't afford to invest. While some stocks may not be attainable buys with a smaller starting amount, you can still build your portfolio with a modest initial investment and set yourself up for healthy fut...
NEW YORK , Aug. 20, 2020 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City , is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may ...
Sanofi agrees to acquire Principia Bio for $3.68 billion Sanofi ( SNY ) announced that it has agree to buy Principia Biopharma Inc. ( PRNB ) for $3.68 billion. The transaction has been unanimously approved by the Boards of Directors of both companies. Sanofi believes that the acquisition...
NEW YORK , Aug. 17, 2020 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City , is investigating Principia Biopharma Inc. ("PRNB" or the "Co...
NEW YORK, NY / ACCESSWIRE / August 17, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Principia Biopharma Inc. (NASDAQ:PRNB) to Sanofi for $100 per share in cash is fair to Principia shareholders. On behalf of Principia shareholders, Halper S...
News, Short Squeeze, Breakout and More Instantly...
Principia Biopharma Inc. Company Name:
PRNB Stock Symbol:
NASDAQ Market:
Principia Biopharma Inc. Website:
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc., a Sanofi company, focused on developing treatments for immune mediated diseases, today announced it has completed patient enrollment into the global Phase 3 PEGASUS trial for rilzabrutinib, an oral inve...
NEW YORK, NY / ACCESSWIRE / September 19, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Maxim Integrated Products, Inc. (NASDAQ: MXIM...
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune mediated diseases, today announced that the first patient was dosed in an open label two-arm trial to e...